AHA 2022: Sustained Blood Pressure Lowering Effect With the Dual Endothelin Receptor Antagonist Aprocitentan in Resistant Hypertension
By
AHA 2022 Conference Coverage
FEATURING
Markus Schlaich
By
AHA 2022 Conference Coverage
FEATURING
Markus Schlaich
1,560 views
November 16, 2022
Comments 2
Login to view comments.
Click here to Login